EC grants orphan drug designation to Zafgen’s beloranib to treat craniopharyngioma
In July last year, the EC granted orphan designation for beloranib to treat Prader-Willi syndrome (PWS). Beloranib is being studied as a first-in-class obesity therapy that shows a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.